COBRE Center for Cancer Research Development

COBRE 癌症研究发展中心

基本信息

批准号：
8882661
负责人：
Bharat Ramratnam
金额：
$ 121.35万
依托单位：
RHODE ISLAND HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-05-01 至 2020-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8882661
关键词：
Address Archives Award Basic Science Bioinformatics Biological Markers Breast Cancer Biology Cancer Research Infrastructure Centers of Research Excellence Clinical Research Core Facility Core Grant Diagnostic Doctor of Philosophy Environment Extramural Activities Faculty Financial Support Freezing Funding Gastrointestinal tract structure Goals Hospitals Housing Image Institution Investigation Investments Liver Malignant Neoplasms Mentors NCI Center for Cancer Research Normal tissue morphology Peer Review Phase Productivity Proteins Proteomics Publications Reporting Research Research Personnel Resources Rhode Island Services Solid Neoplasm Specimen Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Strategic Planning Technology Tissue Sample Tissues Tumor Bank Tumor Tissue United States National Institutes of Health anticancer research base candidate identification clinical material effective therapy gastrointestinal interest mass spectrometer molecular pathology novel marker prognostic programs public health relevance research and development success

项目摘要

DESCRIPTION (provided by applicant): The COBRE Center for Cancer Research Development (CCRD) has become an integral part of the resources and environment of the cancer research infrastructure at RIH. Our Phase I and II periods were characterized by outstanding junior investigator productivity in terms of peer reviewed publications (n=145) and success in obtaining extramural, federal funding ($23,265,020.) The original scientific theme of the Phase I and Phase II awards was to emphasize research on mechanisms of cancer and its origins. This focus on cancer biology will be maintained through the Phase III COBRE by continuing to stimulate awards and core user credits to junior investigators interested in cancer through a new Pilot Grants Core. During the past five years RIH has made a substantial institutional investment in clinical and basic research in cancer. This increase in investigation has had a positive effect on the CCRD Core facilities as it has created an increased local customer base. This expanded customer base will be factored into a strategic plan for sustaining the CCRD core facilities beyond the Phase III period with strong institutional funding. The following four aims are proposed: (Aim 1) To continue to enhance the ability of the Administrative Core to oversee the goals of the COBRE CCRD through maturing of the Molecular Pathology and Proteomics Cores with less reliance on NIH support during Phase III. (Aim 2) To continue to keep the Proteomics Core facility at the cutting edge of rapidly evolving mass spectroscopic technologies associated with global proteomics and identification of candidate proteins in isolation or within tissues. (Aim 3) To provide molecular pathology services including archived tumor bank specimens for enhancing productivity and research capabilities of investigators at all levels of expertise in order to address research problems and to increase their competitiveness for extramural funding. (Aim 4) To provide pilot grants and core user credits to solely support junior investigators interested in cancer research and to offer bioinformatic analysis to recipients of pilot awards.

描述（由申请人提供）：COBRE 癌症研究发展中心 (CCRD) 已成为 RIH 癌症研究基础设施资源和环境的组成部分。我们的第一阶段和第二阶段的特点是初级研究员的生产力出色。同行评审出版物的数量 (n=145) 以及成功获得校外联邦资金 (23,265,020 美元)。第一阶段和第二阶段奖项的最初科学主题是强调癌症及其机制的研究对癌症生物学的关注将通过第三阶段 COBRE 继续保持，通过新的试点资助核心项目继续刺激对癌症感兴趣的初级研究人员的奖励和核心用户积分。癌症临床和基础研究的增加对 CCRD 核心设施产生了积极影响，因为它增加了当地客户群，这一扩大的客户群将被纳入维持 CCRD 核心设施的战略计划中。第三阶段，机构资金雄厚。提出以下四个目标：（目标 1）通过成熟分子病理学和蛋白质组学核心，继续增强行政核心监督 COBRE CCRD 目标的能力，减少对 NIH 在第三阶段支持的依赖（目标 1）。 2 ) 继续保持蛋白质组学核心设施处于与全球蛋白质组学和分离或组织内候选蛋白质鉴定相关的快速发展的质谱技术的前沿（目标 3）。提供分子病理学服务，包括存档的肿瘤库标本，以提高各个专业水平的研究人员的生产力和研究能力，以解决研究问题并提高他们获得外部资金的竞争力（目标 4）提供试点资助和核心用户信贷。专门支持对癌症研究感兴趣的初级研究人员，并向试点奖项的获得者提供生物信息分析。